Status:
COMPLETED
A Study of V950 in People With Alzheimer Disease (V950-001 AM7)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Alzheimer Disease
Eligibility:
All Genders
55+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test the safety, tolerability and the immune response to an investigational vaccine, V950, with or without ISCOMATRIX™ (IMX).
Eligibility Criteria
Inclusion
- Patient has mild to moderate Alzheimer Disease
- Women cannot be able to get pregnant
- Patient has a reliable caregiver, who will attend all visits and answer questions about the patient
Exclusion
- Patient lives in a nursing home or facility
- Patient has another neurological or neurodegenerative disorder
- Patient has a history of stroke
- Patient uses illicit drugs or has a history of drug/alcohol abuse
- Patient has received blood or blood derived products within 6 months
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT00464334
Start Date
March 1 2007
End Date
January 1 2012
Last Update
September 25 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.